Pomegra
Healthleap closed $38M in seed and Series A funding led by Hummingbird Ventures to flag hospital patients with undiagnosed conditions, starting with malnutrition.
Key Takeaways
- Healthleap raised $38M: an $8M seed co-led by Sequoia Capital and First Round Capital, plus a $30M Series A led by Hummingbird Ventures.
- Hospital partners grew from 3 to more than 50 in a year, and revenue rose more than tenfold.
- Valuation was not disclosed; the company plans to screen for more than 40 conditions.
Lead
Healthleap, a clinical AI startup founded in South Africa in 2022, announced $38M in combined funding on October 7, 2026. The package pairs an $8M seed round, co-led by Sequoia Capital and First Round Capital, with a $30M Series A led by Hummingbird Ventures. The company did not disclose a valuation.
The software reads inpatient records every day and flags patients whose conditions may have gone unrecorded. Healthleap says it now works with more than 50 hospital partners, up from three a year earlier.
What Does Healthleap Actually Do?
Healthleap connects to a hospital's electronic health record and analyzes the full chart each day: vital signs, lab results, medications and free-text clinical notes. It looks for signals that busy staff rarely have time to cross-reference, such as a passing note about lost appetite, muscle wasting or trouble swallowing.
The product does not diagnose. It surfaces candidates for a clinician to review. Its first and most developed use is disease-related malnutrition, where the company says up to half of hospitalized patients are at risk but fewer than 9% receive a formal diagnosis.
Programs for delirium, aspiration pneumonia, pressure injuries and congestive heart failure are in development. The platform is HIPAA compliant and SOC 2 certified. Pricing and regulatory status were not disclosed.
Who Is Backing It, and What Does the Round Structure Say?
The round combines two separate financings, and the split matters. The $8M seed, co-led by two of the best-known early-stage firms in the US, funded the period in which Healthleap had a handful of customers. The $30M Series A, led by Hummingbird Ventures, came after the customer base had grown to more than 50 hospital partners.
Announcing both together presents a larger headline figure than either round alone. Read separately, the numbers describe a conventional path: a modest seed, then a Series A roughly four times larger once revenue growth was visible. A tenfold revenue increase is also easier to achieve from a small base, and the company did not disclose absolute revenue.
How Strong Is the Evidence?
Healthleap points to a peer-reviewed study of more than 166,000 admissions that found 88% higher sensitivity than standard screening tools. Customer figures, supplied by the company, are specific. Penn Medicine reported an annualized impact of $23.8M, including 8,632 bed-days saved and $6.3M in additional reimbursement. Cedars-Sinai reported a 39% increase in malnutrition diagnoses and $11M in annual impact.
These figures show where the commercial argument sits. Hospitals are reimbursed more when conditions such as malnutrition are properly documented and coded, and shorter stays free beds. The pitch rests on revenue capture and throughput as much as on patient safety, though the two goals run in the same direction here.
Other named customers include Houston Methodist, Emory Healthcare and Intermountain. The results are self-reported, and independent replication across smaller or community hospitals has not been published.
What Will the Money Fund?
Healthleap plans to spend on engineering, product, sales and customer success. The roadmap targets more than 40 major conditions and an eventual move into outpatient and home care. CEO Josiah Meyer co-founded the company with his sister, Jemima Meyer, a clinical dietitian by training.
"Finding them now is prevention, and it's a win for everyone," Meyer said. "Our goal is to improve care and save lives by catching these conditions early."
What Are the Risks?
The main risk is breadth. Malnutrition has a clear coding pathway and measurable reimbursement. Conditions such as delirium or aspiration pneumonia are harder to detect from records and may not carry the same financial return, which could weaken the sales case for each additional module.
Alert fatigue is the second concern. Hospital clinicians already face a steady stream of automated warnings, and a screening tool that adds false positives risks being ignored. Competition from electronic health record vendors, which can build similar surveillance into their own systems, is a third factor.
Outlook
Healthleap enters its next phase with funding from three well-known venture firms, a customer base that grew from 3 to more than 50 hospitals in a year, and a documented financial case built on malnutrition. The test now is whether the model transfers to conditions with weaker reimbursement and whether the results hold up in independent evaluations. Expansion to outpatient and home care would extend the same approach to settings with thinner clinical staffing.
